search
Back to results

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

Primary Purpose

Esophageal Cancer, Surgery, Neoadjuvant Treatment

Status
Recruiting
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Neoadjuvant immunochemotherapy
Sponsored by
Henan Cancer Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Esophageal Cancer focused on measuring Neoadjuvant chemotherapy, Neoadjuvant immunochemotherapy

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Histologic diagnosis of local advance squamous cell thoracic esophageal carcinoma of Stage (T1N1-3 or T2-3N0-3 M0), (8th Union for International Cancer Control, UICC-TNM).
  2. No metastatic lymph node in cervical by color doppler sonography.
  3. Patients must not have received any prior anticancer therapy of esophageal carcinoma.
  4. Age ranges from 18 to 75 years.
  5. Without operative contraindication.
  6. Absolute white blood cells count ≥4.0×109/L, neutrophil ≥1.5×109/L, platelets ≥100.0×109/L, hemoglobin ≥90g/L, and normal functions of liver and kidney, total bilirubin(TBIL)≤1.5N, aspartate aminotransferase (AST)≤2.5N, alanine aminotransferase(ALT)≤2.5N, prothrombin time(PT)≤1.5N, and activated partial thromboplastin time(APTT) is in normal range, endogenous creatinine clearance rate(CRE)≤1.5N.
  7. Patients must not have diagnosed with other cancer and must not received any prior anticancer therapy except prostatic cancer with more than 5 years disease-free survival(DFS).
  8. expected R0 resection.
  9. ECOG 0~1.
  10. Patients should agree to use contraceptive measures during the study period and within 6 months of the end of the study. Women must be non-lactation.
  11. Signed informed consent document on file. 10. .

Exclusion Criteria:

  • 1. Multiple primary cancer. 2.Patients with infections disease that require treatment 3.Patients who need continuous hormone treatment 4.unstable angina within 3 months, myocardial infarction within 6 months 5.psychopath 6.Patients with concomitant hemorrhagic disease. 7.Any unexpected reason for patients can't get operation 8.Inability to use gastric conduit after esophagectomy because of a prior surgery.

    9.Pregnant or breast feeding 10.Patients are diagnosed or suspected to be allergic to cisplatin or Paclitaxel.

    11.Bronchial asthma who requires intermittent use of bronchodilators or medical interventions 12.Due to co-existing diseases, the immunosuppressant was used. And the dosage of immunosuppressant was more than 10mg/ day orally and more than 2 weeks before enrollment 13.Abnormal coagulation function (PT>16s, APTT>53s, TT>21s, Fib<1.5g/L), tendency of bleeding or receiving thrombolysis or anticoagulant therapy 14.Previous or present pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, lung function severely impaired 15.Autoimmune diseases, immune deficiency, organ transplantation; 16.Hepatitis b/c patients。

Sites / Locations

  • Henan Cancer Hospital (The Affiliated Cancer Hospital of Zhengzhou University)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Neoadjuvant immunochemotherapy

Neoadjuvant chemotherapy

Arm Description

Neo-adjuvant chemotherapy(cisplatin and paclitaxel): Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, >30min, 3week, 2 cycles Surgery: 2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality. Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included). After surgery/ maintain period: JS001, 240mg ivgtt, d3, >30min, 3week (8 cycles at most)

Neo-adjuvant chemotherapy(cisplatin and paclitaxel): Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. Surgery: 2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality. Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).

Outcomes

Primary Outcome Measures

Event-free survival (EFS)
The date from the beginning of randomization to the date of first record of unresectable disease, distant metastases, local recurrences of any causes, and death of any cause.
Event-free survival (EFS)
The date from the beginning of randomization to the date of first record of unresectable disease, distant metastases, local recurrences of any causes, and death of any cause.

Secondary Outcome Measures

pCR
pathological complete response rate
DFS
Disease free survival
DFS
Disease free survival
OS
Overall survival rate
OS
Overall survival rate
ORR
The Overall Response Rate. ORR=CR+PR. Criteria: Response Evaluation Criteria in Solid Tumors, RECIST.
R0 resection rate
the complete resection rate of all tumor under microscope
MPR
MPR rate was defined as the percentage of patients who achieved a major pathological response (residual tumor ≤10%)
EORTC QLQ-C30
EORTC QLQ-C30 repeated measurement model
EORTC QLQ-OES18
EORTC QLQ-OES18 repeated measurement model
NRS-2002
NRS-2002 repeated measurement model

Full Information

First Posted
February 18, 2020
Last Updated
October 2, 2022
Sponsor
Henan Cancer Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04280822
Brief Title
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
Official Title
A Phase III, Randomized Controlled Study of Neo-adjuvant Toripalimab (JS001) in Combination With Chemotherapy Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 21, 2020 (Actual)
Primary Completion Date
December 2, 2023 (Anticipated)
Study Completion Date
March 2, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Henan Cancer Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The effect of neo-adjuvant immunochemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains unknown. One of our objectives is to evaluate whether the neo-adjuvant immunochemotherapy Toripalimab (JS001) with cisplatin and paclitaxel followed by right thoracic approach esophagectomy with total 2-field lymph node dissection improves the overall survival of thoracic esophageal cancer patients versus neo-adjuvant chemotherapy.
Detailed Description
The effect of immunochemotherapy in second line treatment of esophageal cancer got a positive results in the world. We tried to apply the immunotheray in resectable esophageal cancer and have planed this phase III clinical trials. The optimal management of resectable esophageal squamous cell carcinomas may have a new chapter in the era of immunotherapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
Keywords
Neoadjuvant chemotherapy, Neoadjuvant immunochemotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Neoadjuvant immunochemotherapy
Arm Type
Experimental
Arm Description
Neo-adjuvant chemotherapy(cisplatin and paclitaxel): Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, >30min, 3week, 2 cycles Surgery: 2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality. Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included). After surgery/ maintain period: JS001, 240mg ivgtt, d3, >30min, 3week (8 cycles at most)
Arm Title
Neoadjuvant chemotherapy
Arm Type
Active Comparator
Arm Description
Neo-adjuvant chemotherapy(cisplatin and paclitaxel): Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. Surgery: 2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality. Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).
Intervention Type
Drug
Intervention Name(s)
Neoadjuvant immunochemotherapy
Intervention Description
Neo-adjuvant chemotherapy(cisplatin and paclitaxel): Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, >30min, 3week, 2 cycles Surgery: 2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality. Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included). After surgery/ maintain period: JS001, 240mg ivgtt, d3, >30min, 3week (8 cycles at most)
Primary Outcome Measure Information:
Title
Event-free survival (EFS)
Description
The date from the beginning of randomization to the date of first record of unresectable disease, distant metastases, local recurrences of any causes, and death of any cause.
Time Frame
The date from the beginning of randomization to the date of first record. 3 years EFS
Title
Event-free survival (EFS)
Description
The date from the beginning of randomization to the date of first record of unresectable disease, distant metastases, local recurrences of any causes, and death of any cause.
Time Frame
The date from the beginning of randomization to the date of first record. 5 years EFS
Secondary Outcome Measure Information:
Title
pCR
Description
pathological complete response rate
Time Frame
within 14 working days after operation
Title
DFS
Description
Disease free survival
Time Frame
3 years DFS
Title
DFS
Description
Disease free survival
Time Frame
5 years DFS
Title
OS
Description
Overall survival rate
Time Frame
3 years OS
Title
OS
Description
Overall survival rate
Time Frame
5 years OS
Title
ORR
Description
The Overall Response Rate. ORR=CR+PR. Criteria: Response Evaluation Criteria in Solid Tumors, RECIST.
Time Frame
3-4 weeks after the last cycle of neoadjuvant treatment
Title
R0 resection rate
Description
the complete resection rate of all tumor under microscope
Time Frame
within 14 working days after operation
Title
MPR
Description
MPR rate was defined as the percentage of patients who achieved a major pathological response (residual tumor ≤10%)
Time Frame
within 14 working days after operation
Title
EORTC QLQ-C30
Description
EORTC QLQ-C30 repeated measurement model
Time Frame
before surgery, 1month, 3 months, 6 months, 9 months, 1 year after operation
Title
EORTC QLQ-OES18
Description
EORTC QLQ-OES18 repeated measurement model
Time Frame
before surgery, 1month, 3 months, 6 months, 9 months, 1 year after operation
Title
NRS-2002
Description
NRS-2002 repeated measurement model
Time Frame
before surgery, 1month, 3 months, 6 months, 9 months, 1 year after operation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologic diagnosis of local advance squamous cell thoracic esophageal carcinoma of Stage (T1N1-3 or T2-3N0-3 M0), (8th Union for International Cancer Control, UICC-TNM). No metastatic lymph node in cervical by color doppler sonography. Patients must not have received any prior anticancer therapy of esophageal carcinoma. Age ranges from 18 to 75 years. Without operative contraindication. Absolute white blood cells count ≥4.0×109/L, neutrophil ≥1.5×109/L, platelets ≥100.0×109/L, hemoglobin ≥90g/L, and normal functions of liver and kidney, total bilirubin(TBIL)≤1.5N, aspartate aminotransferase (AST)≤2.5N, alanine aminotransferase(ALT)≤2.5N, prothrombin time(PT)≤1.5N, and activated partial thromboplastin time(APTT) is in normal range, endogenous creatinine clearance rate(CRE)≤1.5N. Patients must not have diagnosed with other cancer and must not received any prior anticancer therapy except prostatic cancer with more than 5 years disease-free survival(DFS). expected R0 resection. ECOG 0~1. Patients should agree to use contraceptive measures during the study period and within 6 months of the end of the study. Women must be non-lactation. Signed informed consent document on file. 10. . Exclusion Criteria: 1. Multiple primary cancer. 2.Patients with infections disease that require treatment 3.Patients who need continuous hormone treatment 4.unstable angina within 3 months, myocardial infarction within 6 months 5.psychopath 6.Patients with concomitant hemorrhagic disease. 7.Any unexpected reason for patients can't get operation 8.Inability to use gastric conduit after esophagectomy because of a prior surgery. 9.Pregnant or breast feeding 10.Patients are diagnosed or suspected to be allergic to cisplatin or Paclitaxel. 11.Bronchial asthma who requires intermittent use of bronchodilators or medical interventions 12.Due to co-existing diseases, the immunosuppressant was used. And the dosage of immunosuppressant was more than 10mg/ day orally and more than 2 weeks before enrollment 13.Abnormal coagulation function (PT>16s, APTT>53s, TT>21s, Fib<1.5g/L), tendency of bleeding or receiving thrombolysis or anticoagulant therapy 14.Previous or present pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, lung function severely impaired 15.Autoimmune diseases, immune deficiency, organ transplantation; 16.Hepatitis b/c patients。
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yan Zheng, PhD, MD
Phone
+86+15713660065
Email
sunnyzheng1@126.com
First Name & Middle Initial & Last Name or Official Title & Degree
Haibo Sun, PhD, MD
Email
sunny-haipo@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yan Zheng, PhD, MD
Organizational Affiliation
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Official's Role
Principal Investigator
Facility Information:
Facility Name
Henan Cancer Hospital (The Affiliated Cancer Hospital of Zhengzhou University)
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yan Zheng, PhD
Phone
86-371-65587226
Email
sunnyzheng1@126.com
First Name & Middle Initial & Last Name & Degree
Yan Zheng, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No plan
Citations:
PubMed Identifier
33553366
Citation
Zheng Y, Liu XB, Sun HB, Xu J, Shen S, Ba YF, Yan M, Qin Z, Liu BX, Wang ZF, Liu SL, Zhang RX, Chen PN, Liang GH, Yuan D, Li ZX, Liu Q, Wang HR, Li HM, Lv H, Ma X, Zhu J, Yu YK, Xing WQ; written on Henan Cancer Hospital Thoracic Oncology Group (HCHTOG). A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909). Ann Transl Med. 2021 Jan;9(1):73. doi: 10.21037/atm-20-5404.
Results Reference
derived

Learn more about this trial

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

We'll reach out to this number within 24 hrs